Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
gameil, M., Rozik, S., Elsebaie, A., Marzouk, R. (2021). Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.. EKB Journal Management System, (), -. doi: 10.21608/mjvh.2021.40184.1005
mohammed ali gameil; Salah eldeen Rozik; Ahmed Hassan Elsebaie; Rehab Elsayed Marzouk. "Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.". EKB Journal Management System, , , 2021, -. doi: 10.21608/mjvh.2021.40184.1005
gameil, M., Rozik, S., Elsebaie, A., Marzouk, R. (2021). 'Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.', EKB Journal Management System, (), pp. -. doi: 10.21608/mjvh.2021.40184.1005
gameil, M., Rozik, S., Elsebaie, A., Marzouk, R. Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.. EKB Journal Management System, 2021; (): -. doi: 10.21608/mjvh.2021.40184.1005

Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.

Medical Journal of Viral Hepatitis
Articles in Press, Accepted Manuscript, Available Online from 05 May 2021  XML
Document Type: Original article
DOI: 10.21608/mjvh.2021.40184.1005
View on SCiNiTO View on SCiNiTO
Authors
mohammed ali gameil email orcid 1; Salah eldeen Rozikorcid 2; Ahmed Hassan Elsebaieorcid 3; Rehab Elsayed Marzoukorcid 4
1Endocrine unite,Faculty of Medicine, Mansoura University, Mansoura, Dakahlia, Egypt.
2Gastroenterology and hepatology unite, Internal medicine department, Faculty of Medicine ,Mansoura University, Mansoura, Dakahlia, Egypt.
3Clinical pathology department, Faculty of Medicine, Mansoura University, Egypt.
4Medical biochemistry department, Mansoura University, Egypt.
Abstract
Abstract
Background and study aim: Non-alcoholic fatty liver disease (NAFLD) represents a major public health challenge in patients with type 2 diabetes mellitus (T2D). It may progress to non-alcoholic steatohepatitis( NASH), cirrhosis, and carcinoma. Our aim was to detect the changes of the fatty liver index (FLI) and FIB-4 score six months after treatment with liraglutide, or dulaglutide; novel antidiabetic medications in the Egyptian market versus the conventional therapy alone in Egyptian patients with T2D and co-existent NAFLD. Results: We found a significant improvement of the FIB-4 and FLI values in the patients who used liraglutide and dulaglutide than the conventional treatment and with better results in the liraglutide group. We noticed a significant reduction of the bodyweight, waist circumference, BMI, SBP, DBP, GGT, ALT, AST, HBA1c, triglyceride, total cholesterol, LDL-C and VLDL-C values in the liraglutide and dulaglutide groups versus the conventional treatment group. FLI, AST and Platelet count changes were the significant predictors of the change in log FIB-4 score. However, the change in log FLI was independently affected by ALT changes. Conclusion: the addition of the liraglutide or dulaglutide exhibited many clinical and metabolic beneficial effects in the patients with concomitant T2D and NAFLD.
Keywords
NAFLD; fatty liver index; FIB-4 score; GLP1-RAs
Statistics
Article View: 135